Q
Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

26,521 signal articles · 272 in last 24h · 127,276 total before filter · latest 29m ago
272last 24h
1218last 7d
193● bullish (7d)
124● bearish (7d)
206publishers
AllMacro243Earnings466M&A84Regulatory22Product11Analyst13
✕ clear all filtersSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Can Johnson Controls (JCI) Turn Wasted Heat Into $18B?
Insider Monkey16d agoneutral
Can Johnson Controls (JCI) Turn Wasted Heat Into $18B?

Johnson Controls International (NYSE:JCI) just found a way to sell power that the data center industry was throwing away. On July 28, the company launched its Absorption Chiller Reference Design Guide, a blueprint that converts waste heat from on-site generators into cooling capacity, freeing up electricity that would otherwise go to running chillers. In a […]

AbCellera (ABCL) Rockets 44% as Hot Flash Treatment Brightens Growth Outlook
Insider Monkey17d agoneutral
AbCellera (ABCL) Rockets 44% as Hot Flash Treatment Brightens Growth Outlook

AbCellera Biologics Inc. (NASDAQ:ABCL) rallied for a third consecutive day on Monday to hit a new three-year high, after its drug candidate for hot flashes in menopausal women achieved strong clinical trial results, sparking long-term rosy growth prospects. In intra-day trading, the stock surged to a record high of $10.01 before trimming gains to end […]

Eli Lilly vs. Novo Nordisk: Has GLP-1 Manufacturing Become the New Competitive Moat?
Insider Monkey17d agoneutral
Eli Lilly vs. Novo Nordisk: Has GLP-1 Manufacturing Become the New Competitive Moat?

The obesity-drug market has largely been viewed as a race between clinical innovation and commercial execution. Investors have spent the past three years comparing prescription growth, market share, and pipeline candidates as Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) compete for dominance in one of healthcare’s fastest-growing markets. Yet another competitive advantage for investors to […]

Intel (INTC) Tripled This Year, But Can a $15B Share Sale Stop the Momentum?
Insider Monkey17d agoneutral
Intel (INTC) Tripled This Year, But Can a $15B Share Sale Stop the Momentum?

Intel (NASDAQ:INTC) shares have nearly tripled this year, outrunning AMD (NASDAQ:AMD), Nvidia (NASDAQ:NVDA), and the Philadelphia Semiconductor Index’s nearly 75% climb. On August 10, the company said it would sell $15 billion of new stock to fund its push into contract chip manufacturing, and shares fell more than 4% in early trading. That marked a […]

Investing.com17d agobearish
Morgan Stanley cuts Global-e rating to equal-weight, raises price target to $44

Investing.com -- Morgan Stanley downgraded its view on cross-border e-commerce platform Global-e Online to Equal-weight from Overweight, saying the market now better reflects the company’s durable growth and competitive position. The bank nevertheless raised its price target to $44 from $37 as it rolled its valuation framework forward to 2028 and incorporated the impact of the Passport acquisition.